Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2013 1
2017 2
2018 1
2019 4
2020 3
2021 5
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean r emodi[Author] (5 results)?
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
O'Connell CL, Baer MR, Ørskov AD, Saini SK, Duong VH, Kropf P, Hansen JW, Tsao-Wei D, Jang HS, Emadi A, Holmberg-Thyden S, Cowland J, Brinker BT, Horwood K, Burgos R, Hostetter G, Youngblood BA, Hadrup SR, Issa JP, Jones P, Baylin SB, Siddiqi I, Grønbaek K. O'Connell CL, et al. Among authors: emadi a. Clin Cancer Res. 2022 Dec 15;28(24):5306-5316. doi: 10.1158/1078-0432.CCR-22-1810. Clin Cancer Res. 2022. PMID: 36222848 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: We conducted a Phase I/II, multicenter clinical trial for patients with MDS not achieving an International Working Group response after at least 4 cycles of an HMA ("refractory") or progressing after a response ("relapsed") with 3+ or higher risk MDS by the …
PATIENTS AND METHODS: We conducted a Phase I/II, multicenter clinical trial for patients with MDS not achieving an International Working Gro …
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, Emadi A, Niyongere S, O'Connell CL, Youngblood BA, Baylin SB, Rassool FV. Baer MR, et al. Among authors: emadi a. Clin Cancer Res. 2022 Apr 1;28(7):1313-1322. doi: 10.1158/1078-0432.CCR-21-3729. Clin Cancer Res. 2022. PMID: 35091444 Free PMC article. Clinical Trial.
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Altman JK, Zuckerman T, Koprivnikar J, McCloskey J, Kota V, Keng M, Frankfurt O, Abaza Y, Bixby DL, Emadi A, Burch M, Bhatnagar B, Luger SM, Percival ME, Wolach O, Craig M, Ganzel C, Roboz G, Levi I, Gourevitch A, Flaishon L, Tessler S, Blumberg C, Gengrinovitch S, Ben Yakar R, Rowe JM. Altman JK, et al. Among authors: emadi a. Blood Adv. 2023 Dec 26;7(24):7494-7500. doi: 10.1182/bloodadvances.2023010943. Blood Adv. 2023. PMID: 37903324 Free PMC article. Clinical Trial.
COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance.
Bermas BL, Gianfrancesco M, Tanner HL, Seet AM, Aguiar MC, Al Adhoubi NK, Al Emadi S, Cunha BM, Flood R, Kusevich DA, McCarthy EM, Patel NJ, Ruderman EM, Sattui SE, Sciascia S, Siddique F, Valenzuela-Almada MO, Wise LM, Worthing AB, Zell J, Bhana S, Costello W, Duarte-Garcia A, Grainger R, Gossec L, Hausmann JS, Hyrich K, Lawson-Tovey S, Liew JW, Sirotich E, Sparks JA, Sufka P, Wallace ZS, Machado PM, Strangfeld A, Clowse MEB, Yazdany J, Robinson PC. Bermas BL, et al. Among authors: al emadi s. J Rheumatol. 2022 Jan;49(1):110-114. doi: 10.3899/jrheum.210480. Epub 2021 Sep 1. J Rheumatol. 2022. PMID: 34470798 Free article.
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R, Blonquist TM, Emadi A, Hasserjian RP, Burke M, Lescinskas C, Neuberg DS, Brunner AM, Hobbs G, Hock H, McAfee SL, Chen YB, Attar E, Graubert TA, Bertoli C, Moran JA, Bergeron MK, Foster JE, Ramos AY, Som TT, Vartanian MK, Story JL, McGregor K, Macrae M, Behnan T, Wey MC, Rae J, Preffer FI, Lesho P, Duong VH, Mann ML, Ballen KK, Connolly C, Amrein PC, Fathi AT. Narayan R, et al. Among authors: emadi a. Cancer. 2020 Mar 15;126(6):1264-1273. doi: 10.1002/cncr.32657. Epub 2019 Dec 20. Cancer. 2020. PMID: 31860140 Free article. Clinical Trial.
BACKGROUND: Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies specifically targeting AML are of high interest. ...LAY SUMMARY: The outcomes for patients with relapsed/refractory acute myeloid leukemia (R …
BACKGROUND: Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies speci …
Lightweight End-to-End Deep Learning Solution for Estimating the Respiration Rate from Photoplethysmogram Signal.
Chowdhury MH, Shuzan MNI, Chowdhury MEH, Reaz MBI, Mahmud S, Al Emadi N, Ayari MA, Ali SHM, Bakar AAA, Rahman SM, Khandakar A. Chowdhury MH, et al. Among authors: al emadi n. Bioengineering (Basel). 2022 Oct 16;9(10):558. doi: 10.3390/bioengineering9100558. Bioengineering (Basel). 2022. PMID: 36290527 Free PMC article.
The model provided a root mean squared error (RMSE), mean absolute error (MAE), and correlation coefficient (R) of 1.75 breaths per minute (bpm), 1.27 bpm, and 0.92, respectively, for VORTAL, while these metrics were 1.20 bpm, 0.77 bpm, and 0.92, respectively, for BIDMC. . …
The model provided a root mean squared error (RMSE), mean absolute error (MAE), and correlation coefficient (R) of 1.75 breaths per m …
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.
Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, Jacobsohn L, Ja C, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Schäfer M, Frãzao-Mateus E, Bulina I, Stafford F, Tufan A, Graver C, Yardımcı GK, Zepa J, Al Emadi S, Cook C, Abutiban F, Dey D, Katigbak G, Kaufman L, Kowalski E, Martínez-Martínez MU, Patel NJ, Reyes-Cordero G, Salido E, Smith E, Snow D, Sparks J, Wise L, Bhana S, Gore-Massy M, Grainger R, Hausmann J, Sirotich E, Sufka P, Wallace Z, Machado PM, Robinson PC, Yazdany J. Liew J, et al. Among authors: al emadi s. RMD Open. 2022 Apr;8(1):e002187. doi: 10.1136/rmdopen-2021-002187. RMD Open. 2022. PMID: 35387864 Free PMC article.
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance.
Ugarte-Gil MF, Alarcón GS, Izadi Z, Duarte-García A, Reátegui-Sokolova C, Clarke AE, Wise L, Pons-Estel GJ, Santos MJ, Bernatsky S, Ribeiro SLE, Al Emadi S, Sparks JA, Hsu TY, Patel NJ, Gilbert EL, Valenzuela-Almada MO, Jönsen A, Landolfi G, Fredi M, Goulenok T, Devaux M, Mariette X, Queyrel V, Romão VC, Sequeira G, Hasseli R, Hoyer B, Voll RE, Specker C, Baez R, Castro-Coello V, Maldonado Ficco H, Reis Neto ET, Ferreira GAA, Monticielo OAA, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Costello W, Wallace ZS, Jacobsohn L, Taylor T, Ja C, Strangfeld A, Mateus EF, Hyrich KL, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schäfer M, Machado PM, Robinson PC, Gianfrancesco M, Yazdany J. Ugarte-Gil MF, et al. Among authors: al emadi s. Ann Rheum Dis. 2022 Jul;81(7):970-978. doi: 10.1136/annrheumdis-2021-221636. Epub 2022 Feb 16. Ann Rheum Dis. 2022. PMID: 35172961 Free PMC article.
20 results